Intratumoral delivery of an engineered oncolytic virus, DNX-2401, targeting glioblastoma cells combined with subsequent immunotherapy was safe and improved survival outcomes in a subset of patients with recurrent GBM, according to results from a multi-institutional phase I/II clinical trial co-led by researchers at MD Anderson Cancer Center and the University of Toronto.
Researchers at the University of Texas MD Anderson Cancer Center have developed a novel antibody-toxin conjugate designed to stimulate immune-mediated eradication of tumors.
